Principal Investigator
Elizabeth Berry-Kravis, MD
Rush University Medical Center
- 3 trials
- 1 compound
Therapeutic focus
- Fragile X Syndrome
All trials (3)
| NCT | Phase | Status | Compound | Sponsor |
|---|---|---|---|---|
| NCT05367960 | Phase 3 | Active | Zatolmilast | Tetra Discovery Partners |
| NCT05358886 | Phase 3 | Completed | Zatolmilast | Tetra Discovery Partners |
| NCT01911455 | Phase 1 | Completed | — | Children's Hospital Medical Center, Cincinnati |
Compounds studied
Trial sites (17)
- Salt Lake City, Utah, United States
- Baltimore, Maryland, United States
- Sacramento, California, United States
- Kansas City, Kansas, United States
- New York, New York, United States
- Irvine, California, United States
- Orange, California, United States
- Miami, Florida, United States
- Atlanta, Georgia, United States
- Aurora, Colorado, United States
- Greenville, South Carolina, United States
- Cincinnati, Ohio, United States
- Worcester, Massachusetts, United States
- Chicago, Illinois, United States
- Media, Pennsylvania, United States
- Strasburg, Pennsylvania, United States
- Boston, Massachusetts, United States
Investigator and site data mirrored fromClinicalTrials.gov (public domain).